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Translational relevance:
We describe a new hypofractionated radiotherapy schedule for newly-diagnosed glioblastoma, made possible through anti-permeability and corticosteroid-like effects of bevacizumab. The resulting treatment schedule (6 treatments in two weeks) is more convenient than the standard 30 treatments in [6] [7] weeks, and was associated with comparable survival. Comprehensive exploratory correlative studies were performed to optimize patient selection, and provided new insights into the biology of bevacizumab and hypofractionated radiotherapy in glioblastoma. Analysis of TCGA glioblastoma transcriptional subclasses (Nanostring assay) showed patients with a proneural phenotype achieved unexpectedly poor outcomes, suggesting that in the absence of IDH-1 mutation, this phenotype is a marker of poor, and not better prognosis as previously thought. Dynamic susceptibility-contrast perfusion MRI showed marked decreases in rCBV over time, suggesting a role as a biomarker of anti-angiogenic effects. However, meaningful anti-tumor effects were better captured by imaging techniques based on cell proliferation and metabolism, such as ADC and FDG-PET, which were of prognostic value in this trial. 
Abstract:
PURPOSE: Bevacizumab is associated with decreased vascular permeability that allows for more aggressive radiotherapy schedules. We conducted a phase II trial in newly-diagnosed glioblastoma utilizing a novel hypofractionated stereotactic radiotherapy (HFSRT) schedule combined with temozolomide and bevacizumab.
EXPERIMENTAL DESIGN: Patients with tumor volume ≤60cc were treated with HFSRT (6x6Gy to contrast-enhancement and 6x4Gy to FLAIR hyperintensity with dose painting) combined with concomitant/ adjuvant temozolomide and bevacizumab at standard doses. Primary endpoint was 1-year overall-survival (OS): Promising=70%; nonpromising=50%; α=0.1; β=0.1.
RESULTS: Forty patients were enrolled (median age: 55y; methylated MGMT promoter: 23%; unmethylated: 70%). The 1-year OS was 93% (95%CI 84-100) and median OS was 19m. The median progression-free survival was 10m, with no pseudo-progression observed. The objective response rate (ORR) was 57%. Analysis of TCGA glioblastoma transcriptional subclasses (Nanostring assay) suggested patients with a proneural phenotype (26%) fared worse (ORR=14%, versus 77% for other subclasses; p=0.009).
Dynamic susceptibility-contrast perfusion MRI showed marked decreases in rCBV over time (p<0.0001) but had no prognostic value, whereas higher baseline ADC ratios and Introduction Glioblastoma, the most common and aggressive malignant glioma, is characterized not only by a short survival (1) (2) (3) , but also by a particularly poor quality of life (QoL), as brain function is progressively compromised by both disease burden and effects of treatments (4, 5) ; new therapeutic options are clearly needed.
The standard of care for newly-diagnosed glioblastoma was established in a phase III study testing focal radiotherapy (60 Gy in 2 Gy fractions over 6 weeks) with concomitant and adjuvant temozolomide versus radiotherapy alone (1) . In that study, the chemoradiotherapy arm achieved a median overall survival (OS) of 15 months, compared to 12 months for radiotherapy alone. A post-hoc tissue analysis (6) suggested that tumors with promoter methylation of the DNA repair enzyme O 6 -methylguanine-DNA methyltransferase (MGMT) had a better prognosis; in the chemotherapy arm, the median OS was 22 months for methylated versus 13 months for unmethylated tumors.
In the present study, we sought to optimize this standard first line regimen through two innovative approaches: 1) utilization of an alternative radiotherapy schedule based on aggressive hypofractionation, made possible with the adoption of stereotactic technology and 2) addition of bevacizumab to prevent symptomatic radionecrosis and associated brain edema through decreased vascular permeability resulting from VEGF blockade (7) . Exploratory correlative studies consisted of 1) advanced neuroimaging, including dynamic susceptibility contrast (DSC) MR perfusion, diffusion MRI and FDG-PET; 2) tissue correlates, including analysis of TCGA transcriptional subclasses (8,9)
Research. and expression of angiogenesis and hypoxia-related genes; and 3) evaluation of QoL and neuropsychological testing throughout treatment.
Patients and Methods

Patients
Main inclusion criteria (Supplementary Data 1, online) included histologically confirmed newly-diagnosed glioblastoma, tumor volume≤ 60 cc (approximately 5cm maximum diameter) and age≥18. Exclusion criteria included multicentric disease and contraindication to the use of bevacizumab. Therapeutic anticoagulation (e.g. for venous thromboembolism) was allowed.
Treatment
The study treatment schema is shown in Figure 1 . Starting 4-6 weeks from surgery, the hypofractionated stereotactic radiotherapy (HFSRT) was delivered in 6 treatments over two weeks, typically on a Monday, Wednesday, Friday schedule, as detailed in Supplementary Data 2 (online). Areas with contrast enhancement received 6X6 Gy and areas with FLAIR hyperintensity received 6X4 Gy, with dose painting for homogeneous dose distribution.
Chemotherapy concomitant with HFSRT consisted of bevacizumab 10mg/kg IV on days 1 and 15, and temozolomide 75mg/m2 given orally daily throughout HFSRT, for a total 
Advanced Neuro-Imaging Evaluation
In addition to standard MRI, all patients underwent DSC perfusion MRI at baseline, as well as post-radiotherapy (pre-adjuvant chemotherapy), and every 2 months thereafter.
Supplementary Data 3 (online) details imaging processing and acquisition parameters.
Commercially available software (FuncTools 2.6.9, GE Healthcare) was used to determine perfusion parameters such as relative cerebral blood volume (rCBV), relative peak height (rPH) and peak signal recovery (PSR), as well as apparent diffusion coefficient (ADC). In addition, a dedicated brain FDG-PET scan was obtained after 6 adjuvant cycles for characterization of disease activity and correlation with outcome.
Tissue Correlates
Research. As detailed in Supplementary Data 4, TCGA glioblastoma transcriptional subclasses (8) (proneural, mesenchymal, classical and neural) were assessed from mRNA extracted from formalin-fixed paraffin-embedded tissue obtained at initial surgery, using a gene expression profiling assay (Nanostring nCounter, Seattle, WA) based on 81 genes selected from the initial TCGA publication (8). Genes for which expression levels are known to directly reflect copy number alterations (Supplementary Data 4) were also added to the probe set, along with VEGF target genes (ANGPTL4, CA-9, EGLN-3,
GLUT1 and PDK1).
In a separate analysis, tumor MGMT promoter methylation status was determined utilizing real-time methylation-specific PCR, as described previously (6) . IDH1 R132H mutation status was determined by immunohistochemistry (Dianova, Hamburg, Germany; 1:30).
Neuropsychological evaluation
Prospective neuropsychological evaluations (10) (11) (12) were performed in consenting, progression-free, patients at baseline and four, eight and twelve months. Raw test scores were compared with published normative values according to age and education, and converted into z-scores; a z-score ≤ -1.5 represents impairment. 
Statistics
The primary endpoint was survival probability at one year (1y-OS). A single stage binomial design was utilized, with 1y-OS of 70% considered promising and 50% nonpromising; α=0.1; β=0.1. Forty patients were to be enrolled; if ≥24 were alive at one year, the regimen would be considered worthy of further study. Secondary endpoints consisted of progression-free survival (PFS), response rate (Macdonald (13) and RANO criteria (14)) and toxicity profile (NCI-CTCAE v3). Exploratory endpoints included feasibility and preliminary evaluation of the prognostic value of advanced neuroimaging parameters and tissue-based biomarkers, as well as QoL and neuropsychological evaluation. Neuropsychological test scores were summarized using descriptive statistics, and longitudinal trajectories evaluated using linear mixed models (LMMs) controlling for age and fatigue. Exact follow-up assessment times from baseline were calculated, and both linear and quadratic terms were estimated by the LMMs. Table 1 shows the characteristics of the 40 patients enrolled.
Results
Patient Characteristics
Treatment and toxicity
Treatment was generally well tolerated and followed the established toxicity profile of each drug (Supplementary Data 5, online). One patient discontinued bevacizumab because of thrombotic microangiopathy with irreversible grade 4 renal failure. One patient developed grade 4 surgical wound infection without dehiscence but was able to resume treatment. Two patients had grade 4 pulmonary embolism and one experienced a late ischemic stroke. One patient with a history of difficult to control seizures died suddenly during sleep, while on treatment; autopsy found no tumor hemorrhage or thromboembolic event. CNS bleeding was reported in two patients, both asymptomatic:
One grade 1 intra-tumoral hemorrhage and one grade 1 hemorrhage in a pre-existing cavernoma, in a patient receiving concomitant full-dose anticoagulation.
A total of 11 patients elected to continue treatment beyond the required 6 adjuvant cycles. Those patients received a median of 12 cycles in total (range: 7-23 cycles). No patient developed worsening of symptoms or radiographic pseudoprogression within the first four months following radiotherapy. In patients free of progression, the KPS was maintained throughout treatment, and the use of corticosteroids significantly decreased over time (p< 0.0001; Figure 3B ). The mean daily dexamethasone dose at baseline was 2.8 mg; following radiotherapy: 1.5 mg; at 6 months: 0.2 mg. Three patients thought to have tumor progression manifest by increased FLAIR hyperintensity without increased contrast enhancement underwent surgical resection; on pathology, tumor progression was confirmed in one patient, and two had mostly necrotic tissue. 
Exploratory Tissue Correlates
MGMT promoter methylation status could be determined in 37 patients, and was methylated in 23% and unmethylated in 70%. There was no association between MGMT status and response (P=1.0), PFS (P=0.39) or OS (P=0.56, Figure 2D ).
The transcriptional glioblastoma subclass was determined in 31 patients (Table 3) There were no statistically significant differences in age distribution according to glioblastoma subclass or MGMT promoter methylation.
Among the 25 patients with sufficient tissue for immunohistochemistry, none displayed the IDH-1 R132H mutation, including all of the evaluated proneural tumors.
The expression levels of angiogenesis and hypoxia-related genes had no prognostic value. Similarly, we found no correlations between inferred copy number alterations based on gene expression data and patient outcome. There were no significant changes in mood, self-reported QoL or fatigue across the study period.
Discussion
In this phase II trial, patients with newly diagnosed glioblastoma were treated with a hypofractionated radiotherapy schedule in combination with bevacizumab and temozolomide, and achieved a 1y-OS of 93%, median OS of 19 months and median PFS of 10 months. As compared to standard chemoradiotherapy, this regimen constituted a more convenient treatment option for patients, given the decreased use of corticosteroids and a notably shorter radiotherapy schedule, consisting of 6 treatments within two weeks, instead of the standard 30 treatments delivered daily over 6-7 weeks.
The value of adding bevacizumab to standard chemoradiotherapy for newly diagnosed glioblastoma is currently a matter of debate. Prospective phase II studies testing this inferiority trial designs have not been used. Also under investigation is the use of hypofractionation and IMRT in escalation studies to deliver higher tumor biological effective doses, although an increased corticosteroid requirement and radionecrosis are major deterrents to the wide application of such schedules (21,28-32). In our study, the addition of bevacizumab appears to have offset the development of symptoms and radiographic signs of radionecrosis typically associated with hypofractionation, decreasing the need for corticosteroids. Interestingly, pathology in some of our reoperated patients showed signs of significant tissue damage; it is possible that other patients thought to have non-enhancing tumor progression in fact had non-enhancing treatment effects. It must also be noted that results of our exploratory neuropsychological testing showed some transient radiotherapy effects on neurocognitive functions, which seemed less marked in comparison to standard fractionation schedules (33) , although definitive conclusions are limited by our small patient number, lack of a control arm and confounding effects of bevacizumab. Analysis of RTOG 0825 (19) suggested that the addition of bevacizumab resulted in more frequent cognitive decline as compared to standard chemoradiotherapy, although interpretation of such findings is limited by the fact that progressing patients were not evaluated, and patients remained longer on study in the bevacizumab arm, which implies that the cognitive decline could represent unrecognized tumor progression, rather than direct bevacizumab effects.
The survival curve in our trial followed the typical pattern observed in bevacizumab glioblastoma studies, with a decrease in early death rates, but no improvement in later survival endpoints in comparison to contemporary phase II historical controls, which have reported median OS of 18-19 months (34) . Therefore, identifying imaging and tissue-based biomarkers and subgroups of patients who benefit from, or who are harmed by, this type of treatment remains crucial (35). We examined bevacizumab effects on tumor blood perfusion as measured by DSC-MRI, and found a nearly universal decrease in blood perfusion over time, demonstrating that the intended targeting of angiogenesis was accomplished. However, for prognostic purposes, diffusion-based parameters were more helpful. Tumors with the lowest ADCs appeared to benefit most perhaps representing highly hypoxic, or densely cell-packed phenotypes, therefore constituting optimal candidates for anti-angiogenic treatments (36). Interestingly, we found the FDG-PET at the 6-month time point to be a reliable marker of treatment failure ( Figure 2E ), even when other imaging modalities suggested stability. Taken together, our findings support the use of imaging techniques based on cell proliferation and metabolism, rather than perfusion and vasculature imaging, to guide future development of anti-angiogenic therapies.
Finally, we evaluated a range of potential tissue-based biomarkers implicated in glioblastoma and angiogenesis. A previous study in recurrent malignant gliomas suggested that high VEGF expression as determined by immunohistochemistry was associated with increased response to bevacizumab but did not predict survival, whereas expression of CA9 was associated with poor survival outcome (35). In our study, we focused on applying the TCGA-based transcriptional classification, under the hypothesis that the marked differences in oncogenetic and angiogenic drivers across distinct expression signatures might translate into differential responses to anti-VEGF therapy. Unexpectedly, results suggested that proneural glioblastomas were associated 
with worse outcomes as compared to other subclasses. Proneural glioblastomas had previously been associated with dysregulated PDGF signaling (8,37,38) and a relatively favorable prognosis (37), in sharp contrast to our findings. Subsequent work, however, suggested that the majority, if not the entirety, of this prognostic advantage derived from the enrichment of the proneural subclass with IDH-mutant tumors, a well-known predictor of prolonged survival (8,9). None of the proneural tumors in our study expressed mutant IDH-1, which may explain their poor outcome in this group. Based on our results, a post hoc analysis of tissue collected in the AVAGLIO study has been initiated, utilizing our Nanostring-based methodology. Preliminary results showed that proneural glioblastomas without IDH-1 mutation were associated with a poor prognosis in the placebo arm, confirming our finding that this molecular signature is associated with a poor prognosis, and suggesting this is not associated with a detrimental effect of bevacizumab in these patients. In fact, additional analysis suggested that adding bevacizumab may actually improve survival in these poor prognosis patients, a finding that will require further validation in larger, prospective studies. Interestingly, in our trial, patients with mesenchymal tumors benefitted from treatment and did not fare worse than other subclasses, which is consistent with their high VEGF expression. This finding contrasts with a preliminary analysis of the RTOG 0825 study, which found that some mesenchymal-associated genes conferred a worse prognosis in patients exposed to bevacizumab (39). Further studies are needed to determine whether this discrepancy is explained by our small number of patients, differing tissue study techniques, or to an effect unique to the hypofractionated radiotherapy schedule utilized in this study. Our study has a number of limitations. Results are applicable to unifocal tumors, with a volume of 60 cc or less. However, for the most part, our population of patients had prognostic factors comparable to historical controls (34) . Many trials used as historical controls have also excluded multifocal tumors (2, 19) and larger tumors are also often excluded because of poor KPS. Another limitation is that a baseline FDG-PET was not obtained, and therefore it is not possible to determine whether the hypermetabolism observed at the sixth month was already present at the time of treatment start, or if developed throughout treatment. Finally, our correlative studies and neuropsychological testing are limited by small patient numbers, and few long-term survivors. Our analyses should be regarded as exploratory and hypothesis-generating; further investigations in larger, randomized studies will be necessary to validate our findings and determine whether potential biomarkers are of a predictive or prognostic value.
In summary, we describe a new use for bevacizumab in newly diagnosed glioblastoma, capitalizing on the anti-permeability effects to develop a convenient hypofractionated radiotherapy schedule. In our hands this regimen was found to be safe, associated with minimal detrimental effects on QoL, and with survival results comparable to other regimens. Our prospective correlative studies provide new insights into the biology of bevacizumab and hypofractionated radiotherapy in glioblastoma, and uncover candidate imaging and tissue-based biomarkers with either prognostic or predictive value that warrant further investigation in adequately powered randomized studies. 
